Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Benzocaine and its salts for parenteral or ophthalmic use II SEP / 98
Benzocaine and its salts. for topical use on mucous membranes for teething III SEP / 98
Benzocaine and its salts.. for topical application on the skin U
Benzonatate III SEP / 98
Benzoyl peroxidePDL

in concentrations greater than 5% or when sold in combination with another medicinal ingredient

I DEC / 13
Benzoyl peroxide. preparations of 5% or less as a single ingredient U MAY / 08
BenzphetamineC1 I JUN / 02
Benztropine or its saltsPDL

including but not limited to benzatropine

I DEC / 13
Benzydamine or its saltsPDL I DEC / 13
Benzyl benzoate II SEP / 98
BenzylmorphineN I JUN / 02
Bepotastine or its salts or derivativesPDL I NOV / 16
BeractantPDL I DEC / 13
Berberis vulgaris Barberry III SEP / 98
Besifloxacin or its saltsPDL I DEC / 13
BetacetylmethadolN I JUN / 02
Betahistine or its saltsPDL I DEC / 13
Betaine or its saltsPDL

for human use, when sold or recommended for the treatment of homocystinuria

I DEC / 13
Betaine or its salts.

for veterinary use

I DEC / 13
BetameprodineN I JUN / 02
BetamethadolN I JUN / 02
BetaprodineN I JUN / 02
Betaxolol or its saltsPDL I DEC / 13
Bethanechol chloridePDL I DEC / 13
Bethanidine or its saltsPDL I DEC / 13
BevacizumabPDL I DEC / 13
Bezafibrate or its salts or derivativesPDL I DEC / 13
BicalutamidePDL I DEC / 13
Bilastine or its salts or derivativesPDL I AUG / 16
Bile salts U
Bioflavanoids U
Biperiden or its saltsPDL I DEC / 13
Bisacodyl when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl U JAN / 14
Bisacodyl and its salts

(except when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)

III JAN / 14
Bishydroxycoumarin or its salts or derivativesPDL I DEC / 13
Bisoprolol or its saltsPDL I DEC / 13
Bitolterol or its saltsPDL I DEC / 13
BivalirudinPDL I DEC / 13
BleomycinPDL I DEC / 13
BlinatumomabPDL I AUG / 16
Boceprevir or its derivativesPDL I DEC / 13
BolandiolC3 I JUN / 02
BolasteroneC3 I JUN / 02
BolazineC3 I JUN / 02
BoldenoneC3 I JUN / 02
BolenolC3 I JUN / 02
Boric acid and its salts in preparations for systemic use, or ophthalmic preparations in concentrations over 2%[Note: does not apply to contact lens solutions intended to be rinsed off prior to insertion in the eye] II DEC / 98
Boric acid and its salts. in ophthalmic preparations in concentrations up to and including 2%, and in contact lens solutions intended to be rinsed off prior to insertion into the eye U DEC / 98
BortezomibPDL I DEC / 13
Bosentan or its salts or derivativesPDL I DEC / 13
Bosutinib or its saltsPDL

including but not limited to Bosutinib methanoate

I AUG / 14
Botulinum toxinPDL

including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B

I DEC / 13
Brentuximab vedotinPDL I DEC / 13
Bretylium tosylatePDL I DEC / 13
Brexpiprazole or its saltsPDL I APR / 17
Brimonidine or its saltsPDL I DEC / 13
Brivaracetam or its derivativesPDL I AUG / 16
BromalPDL I DEC / 13
Bromal hydratePDL I DEC / 13
Bromazepam and its saltsTS I SEP / 98
BrometonePDL I DEC / 13
Bromfenac or its saltsPDL I MAY / 15
BromisovalPDL I DEC / 13
Bromocriptine or its saltsPDL I DEC / 13
BromoformPDL I DEC / 13
Brompheniramine and its salts as a single entity for the treatment of allergies III JAN / 03
Brompheniramine and its salts. in combination products for the relief of cough and cold symptoms U JAN / 03
BrotizolamTS I JUN / 02
Buclizine II SEP / 98
Bufexamac II SEP / 98
Bumetanide or its salts or derivativesPDL I DEC / 13
Bupivacaine and its salts for topical use on mucous membranes except lozenges III SEP / 98
Bupivacaine and its salts for parenteral or ophthalmic use II SEP / 98
BuprenorphineN I JUN / 02
Bupropion or its saltsPDL I DEC / 13
Buserelin or its saltsPDL I DEC / 13
Buspirone or its saltsPDL I DEC / 13
BusulfanPDL I DEC / 13
ButabarbitalC2 I JUN / 02
Butacaine and its salts for ophthalmic or parenteral use II SEP / 98
ButalbitalC2 I JUN / 02
ButallylonalC2 I JUN / 02
Butaperazine or its saltsPDL I DEC / 13
Butenafine 1% cream U SEP / 99
ButethalC2 I JUN / 02
Butoconazole or its saltsPDL I DEC / 13
Butorphanol and any salt thereofC2 I JUN / 02
Butyl chloral hydratePDL I DEC / 13
Cabergoline or its saltsPDL I DEC / 13
CalcipotriolPDL I DEC / 13
CalcitoninPDL I DEC / 13
CalcitriolPDL I DEC / 13
Calcium bromidePDL I DEC / 13
Calcium bromolactobionatePDL I DEC / 13
Calcium carbimidePDL I DEC / 13
Calcium chloride in injectable form for parenteral nutrition I JAN / 03
Calcium disodium edetate II SEP / 98
Calcium gluconate in injectable form for parenteral nutrition I JAN / 03
Calcium polycarbophil III SEP / 98
Calcium salts when sold for the treatment of hyperphosphatemiaPDL I DEC / 13

1876 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled